BeyondSpring (NASDAQ:BYSI – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Risk & Volatility
BeyondSpring has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
Profitability
This table compares BeyondSpring and Cyclerion Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeyondSpring | N/A | N/A | N/A |
| Cyclerion Therapeutics | -77.02% | -24.61% | -22.43% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeyondSpring | 1 | 0 | 0 | 0 | 1.00 |
| Cyclerion Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
This table compares BeyondSpring and Cyclerion Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeyondSpring | $1.75 million | 36.64 | -$11.12 million | ($0.15) | -10.60 |
| Cyclerion Therapeutics | $2.00 million | 3.24 | -$3.06 million | ($0.75) | -2.20 |
Cyclerion Therapeutics has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Cyclerion Therapeutics beats BeyondSpring on 6 of the 11 factors compared between the two stocks.
About BeyondSpring
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
